Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ADVIL FLAVORED versus KETOROLAC TROMETHAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ADVIL FLAVORED versus KETOROLAC TROMETHAMINE.
CHILDREN'S ADVIL-FLAVORED vs KETOROLAC TROMETHAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, resulting in antipyretic, analgesic, and anti-inflammatory effects.
Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing pain and inflammation.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription, up to 3200 mg/day under medical supervision.
10 mg orally every 4-6 hours, not to exceed 40 mg per day; or 15-30 mg intramuscularly or intravenously every 6 hours, not to exceed 120 mg per day (maximum 60 mg for single dose).
None Documented
None Documented
2-4 hours in children; prolonged in neonates (up to 30 hours) and hepatic impairment.
Terminal half-life is 5-6 hours in young adults, prolonged to 9-10 hours in elderly patients (≥65 years) and up to 12-15 hours in renal impairment (CrCl <30 mL/min). Context: q6h dosing interval recommended; accumulation risk in elderly/renal impairment.
Renal excretion of conjugated metabolites (75-80% as glucuronide and sulfate conjugates, <10% as unchanged drug); biliary/fecal elimination accounts for <5%.
Primarily renal excretion: ~92% of dose excreted in urine as parent drug (60%) and metabolites (p-hydroxyketorolac, conjugated forms). Fecal excretion accounts for ~6%. Biliary excretion is minimal.
Category C
Category D/X
NSAID
NSAID